International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 113202 Total View: 1776924
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH

Theory and Application of Mufangji Decoction in the Treatment of Heart Failure

Shuai Wang1, Junru Zhang2,*

1First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, 712000, Shaanxi, China.

2Department of Cardiology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, 710000, Shaanxi, China.

*Corresponding author: Junru Zhang

Published: November 22,2021


Heart failure (HF) is one of the common cardiovascular diseases in clinic, and its mortality rate and readmission rate are high, which is the difficulty and focus of current research. In recent years, the treatment based on syndrome differentiation of traditional Chinese medicine and multi-target treatment of traditional Chinese medicine have attracted researchers’ attention and become a new breakthrough in the treatment of heart failure. Mufangji Decoction is the classic prescription for treating compartment Zhiyin. Clinical research shows that Mufangji Decoction and its modified prescriptions can significantly improve the clinical symptoms of patients with heart failure. Increasing EF value and decreasing BNP level have a positive effect on the treatment of heart failure. This paper summarizes the theoretical, experimental and clinical research progress of Mufangji Decoction in the treatment of heart failure, with a view to providing unique exploration ideas for the treatment of heart failure and benefiting the clinic.


[1] Wang Hua, Liang Yanchun. (2018). Chinese guidelines for diagnosis and treatment of heart failure 2018 [J]. Chinese Journal of Cardiology, 2018, 46(10): 760-789.

[2] Chen Keji, Wu Zonggui, et al. (2016). Expert consensus on Integrated Traditional Chinese and Western medicine diagnosis and treatment of chronic heart failure [J]. Chinese Journal of Integrated Traditional and Western Medicine, 2016, 36(02): 133-141.

[3] Li Xiaoqian, He Jiancheng, Cao Xuebin. (2014). Characteristic Research on TCM Syndrome Factors of Congestive Heart Failure [J]. Chinese Archives of Traditional Chinese Medicine, 2014, 32(9): 2132-2135.

[4] Yuan Qi, Zhao Ping, Feng Jiayin. (2021). Research Progress of Integrated Traditional Chinese and Western Medicine in Treatment of Congestive Heart Failure [J/OL]. Medical Recapitulate, 2021(20): 4097-4101.

[5] Su Ruwang, Zhu Li, Qi Wensheng. (2020). Discussion on prescription and syndrome of mufangji decoction [J]. Guiding Journal of Traditional Chinese Medicine and Pharmacy, 2020, 26(09): 109-111

[6] Zhai Changming, Lu Fang, et al. (2020). Ye Tianshi’s inheritance and development of Zhongjing Fangji [J]. Global Traditional Chinese Medicine, 2020, 13(02): 289-292.

[7] Gu Jingjing, ed. (2007). Yang Pengju, school note. Shennong herbal classic [M]. 3rd Edition. Beijing: Xueyuan publishing house, 2007: 149.

[8] Qian Jing, Cui Yanjing, Qi Wensheng. (2011). Effect of modified mufangji Decoction on BNP and EF in patients with Yang deficiency, blood stasis and water withdrawal syndrome of chronic congestive heart failure [J]. Beijing Journal of Traditional Chinese Medicine, 2011, 30(08): 567-569.

[9] Lu Weiya, Zhang Yunqing, et al. (2021). Clinical efficacy of juanying Ningxin Decoction in the treatment of chronic left heart failure and its effect on serum NT proBNP, GDF-15 and ultrasonic cardiac function indexes [J]. Journal of Hebei Traditional Chinese Medicine and Pharmacology, 2021, 36(01): 15-18.

[10] Wu Jinfei. (2020). Clinical Observation on Classical Prescription in the Treatment of Chronic Heart Failure Due to Yang Deficiency of Heart and Kidney [J]. Chinese Medicine Modern Distance Education of China, 2020, 18(08): 80-82.

[11] Lei Linli, Zeng Xiaoshi, Peng Chan. (2021). Efficacy of modified Mufangji Decoction in treating acute attack of chronic heart failure and its influence on patients’ heart function and NT-proBNP level [J]. Hainan Medical Journal, 2021, 32(10): 1241-1244.

[12] Zhang Meiyu, Hou Shuangshuang, Zhuang Yuan. (2016). Clinical and Experimental Research Summary of Mufangji Decoction [J]. Journal of Liaoning University of Traditional Chinese Medicine, 2016, 18(01): 116-119.

[13] National Pharmacopoeia Committee. (2010). Pharmacopoeia of the people’s Republic of China [M]. Beijing: China Pharmaceutical Science and Technology Press, 2010. 

[14] Dai Shixue, Liu Qiang, Zheng Xuebao. (2006). Pharmacological mechanism and clinical application of Shenfu Decoction in treating heart failure [J]. Journal of Shaanxi University of Chinese Medicine, 2006(05): 56-58.

[15] Gao Xuemin. (2002). Traditional Chinese medicine [M]. Beijing: China traditional Chinese medicine press, 2002: 274.

[16] Kong Xiao-xu, Zuo Hong-yan, Li Yang. (2020). Pharmacological effects and clinical application of tetrandrine: research advances [J]. Journal of International Pharmaceutical Research, 2020, 47(07): 496-501.

[17] Xu Lin, Gong Yiping, et al. (2015). Effects of Modified Mufangji Decoction on Ca ~ (2+)-ATPase in sarcoplasmic reticulum and myocardial remodeling in rats with ischemic heart failure [J]. Chinese Archives of Traditional Chinese Medicine, 2015, 33(09): 2220-2224.

[18] Li Baixue, Wu Wenjun, et al. (2021). Improvement of mufangji Decoction on right heart failure model rats induced by monocrotaline induced pulmonary hypertension and its mechanism based on the regulation of nuclear receptor LXR [J]. Lishizhen Medicine and Materia Medica Research, 2021, 32(06): 1324-1327.

[19] Yanct, C. W., Jessup, M., Bozkurt, B., et al. (2013). AC-CF/AHA guideline for the management of heart failuer; executive summary; a report of the American college of cardiology Foundation/American Heart Association Takk Force on Practice Guidelines [J]. Circulation, 2013, 128(16): 1810-1852. 

[20] Cui Wenji. (2017). Effect of Yangxin Decoction on ca2-can-nfat3 signal pathway in rats with chronic heart failure [D]. Heilongjiang University of Traditional Chinese Medicine, 2017.

[21] Li Xiaoqian, Huang Pinxian, et al. (2020). Transforming growth factor β1 is a differentially expressed candidate protein of congestive heart failure with Qi-deficiency-blood-stasis syndrome [J]. J Tradit Chin Med., 2020, 40(2): 311-316.

How to cite this paper

Theory and Application of Mufangji Decoction in the Treatment of Heart Failure

How to cite this paper: Shuai Wang, Junru Zhang. (2022) Theory and Application of Mufangji Decoction in the Treatment of Heart FailureInternational Journal of Clinical and Experimental Medicine Research6(1), 5-9.